uBriGene Partners with Everlife Biomed to Advance iPSC Therapy Preparation

China-based uBriGene, a leading cell and gene therapy contract development and manufacturing organization (CDMO), has announced a strategic partnership with Everlife Biomed (Beijing) Co., Ltd., a biopharmaceutical company specializing in human immune privilege cell technology. The collaboration will focus on the development of induced pluripotent stem cells (iPSC) therapy preparations, with no financial details disclosed.

The Potential of iPSC in Cell Therapy
Induced pluripotent stem cells (iPSCs) hold the theoretical potential to differentiate into any human organ or tissue, showcasing broad application prospects across medical fields, particularly in cell therapy. The iPSC cell line, which has undergone gene editing and cloning screening, can facilitate the development of efficient, stable, and safe cell drugs. This is achieved through large-scale production and stringent quality control measures, which can significantly reduce treatment costs and improve accessibility.

Collaboration for Medical Innovation
The partnership between uBriGene and Everlife Biomed aims to leverage their respective expertise to advance the field of iPSC therapy. By combining uBriGene’s CDMO capabilities with Everlife Biomed’s focus on immune privilege cell technology, the joint effort has the potential to revolutionize cell therapy and offer innovative treatment options for various medical conditions.-Fineline Info & Tech

Insight, China's Pharmaceutical Industry